Showing results (931-940 of 2,815) with videos related to

Sort By:
Pageof 282
Diabetes Technology & Therapeutics|November 25, 2003
Glucose sensors and the alternate site testing-like phenomenon: relationship between rapid blood glucose changes and glucose sensor signalsTheodor Koschinsky, Karsten Jungheim, Lutz Heinemann
Diabetes Technology & Therapeutics|November 25, 2003
Systemic effects of shock and resuscitation monitored by visible hyperspectral imagingRobert Gillies, Jenny E Freeman, Leopoldo C Cancio, et al.
Diabetes Technology & Therapeutics|April 21, 2017
Performance of an Artificial Pancreas System for Young Children with Type 1 DiabetesMark D DeBoer, Marc D Breton, Christian Wakeman, et al.
Diabetes Technology & Therapeutics|August 7, 2019
Real-World Data from the First U.S. Commercial Users of an Implantable Continuous Glucose SensorPatricia Sanchez, Samanwoy Ghosh-Dastidar, Katherine S Tweden, et al.
Diabetes Technology & Therapeutics|August 9, 2019
Rationale and Design for a GRADE Substudy of Continuous Glucose MonitoringMary E Larkin, David M Nathan, Ionut Bebu, et al.
Diabetes Technology & Therapeutics|November 8, 2018
An Intervention by a Patient-Designed Do-It-Yourself Mobile Device App Reduces HbA1c in Children and Adolescents with Type 1 Diabetes: A Randomized Double-Crossover StudyPhilippe Klee, Catherine Bussien, Montserrat Castellsague, et al.
Diabetes Technology & Therapeutics|February 21, 2019
Continuous Glucose Monitoring in Children with Type 1 Diabetes Improves Well-Being, Alleviates Worry and Fear of HypoglycemiaSze May Ng, Helen S Moore, Marisa F Clemente, et al.
Diabetes Technology & Therapeutics|November 23, 2021
A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe HypoglycemiaNaila Celeste Bailey, Jeannett Dimsits, Mette Hammer, et al.
Diabetes Technology & Therapeutics|July 27, 2019
Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and GastroparesisHarsahiba Kaur, Nicole Schneider, Laura Pyle, et al.
Diabetes Technology & Therapeutics|July 24, 2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 DiabetesThomas Danne, Jeremy Pettus, Andrea Giaccari, et al.
Pageof 282